Use precise geolocation data. Actively scan device characteristics for identification. Store and/or access information on a ...

Forbes 30 Under 30 alum Kimberley Ho walked away from her Wall Street career to launch Evereden for Generation Alpha. Today, ...

Do you have dry, itchy, painful hands? Living with chronic hand eczema (CHE) isn’t just physically taxing—the constant ...

Landmark four-year joint study led by NUH and NUS Medicine, in collaboration with KKH, NUP and SSHSPH, is the first and ...

A new immune-modulating treatment has shown promising results for treating moderate to severe eczema, delivering fast itch ...

SHOPPING: For years, I tried every cream, steroid, and remedy for my chronic eczema with no lasting results-until I discovered a $30 lotion that completely transformed my skin.

Ruxolitinib 0.75% cream and ruxolitinib 1.5% cream are effective and well-tolerated in children aged 2 to 11 years with atopic dermatitis.

GSK’s approval expands belimumab treatment options, offering a first-of-its-kind subcutaneous option that can be administered ...

Reuters, the news and media division of Thomson Reuters, is the world’s largest multimedia news provider, reaching billions of people worldwide every day. Reuters provides business, financial, ...

Tweens’ prefrontal cortex, the brain’s decision-making center, is hardly developed. These kids lack impulse control and react ...

The FDA has extended the Prescription Drug User Fee Act (PDUFA) action date for the topical formulation of the JAK inhibitor ruxolitinib as a treatment of atopic dermatitis (AD) in children aged 2-11 ...

The U.S. Food & Drug Administration (FDA) has granted approval for a new subcutaneous autoinjector formulation of belimumab ...